Patients with breast cancer who have a specific genetic defect in the liver enzyme do not respond well enough to tamoxifen therapy.
Disruption of the metabolism of this drug leads to an increased risk of fatalities and more frequent recurrences of cancer...
19 January 2018, 17:05 ()